# SNAI1

## Overview
SNAI1 is a gene that encodes the protein Snail family transcriptional repressor 1, a zinc finger transcription factor involved in the regulation of epithelial-mesenchymal transition (EMT) and other critical cellular processes. The SNAI1 protein is characterized by its zinc finger domains, which enable it to bind to specific DNA sequences and function as a transcriptional repressor. This protein plays a pivotal role in developmental processes, such as embryogenesis and tissue remodeling, by modulating the expression of genes involved in cell adhesion and motility. Additionally, SNAI1 is implicated in pathological conditions, including cancer metastasis, where it contributes to the invasive and metastatic potential of tumor cells by repressing epithelial markers like E-cadherin (Nieto2002The; Razmara2021Functions).

## Structure
The SNAI1 protein, encoded by the SNAI1 gene, is a zinc finger transcriptional repressor involved in various biological processes, including epithelial-mesenchymal transition (EMT) and cancer metastasis. Its primary structure includes several key domains: an N-terminal SNAG domain, a central serine-rich domain (SRD) adjacent to a nuclear export sequence (NES), and a C-terminal zinc finger domain with four C2H2-type zinc fingers (Razmara2021Functions; Dong2021Epigenetic). The SNAG domain is crucial for recruiting corepressors like the Polycomb complex 2 and the Sin3A/histone deacetylases1/2 complex, which are involved in gene repression (Razmara2021Functions). The zinc finger domains facilitate DNA binding through E-box sequences (CAGGTG) (Dong2021Epigenetic).

The secondary structure of SNAI1 is characterized by the formation of alpha helices within the zinc finger domains, which are essential for DNA interaction. The tertiary structure involves the folding of these domains to enable specific DNA binding. SNAI1 typically functions as a monomer, lacking a quaternary structure.

Post-translational modifications, such as phosphorylation, ubiquitination, acetylation, and sumoylation, play significant roles in regulating SNAI1's stability, activity, and localization, which are critical for its involvement in cancer metastasis (Dong2021Epigenetic).

## Function
The SNAI1 gene encodes a zinc finger transcription factor that plays a critical role in the epithelial-mesenchymal transition (EMT), a process essential for various physiological functions in healthy human cells. SNAI1 functions primarily as a transcriptional repressor, notably inhibiting the expression of E-cadherin, a key epithelial marker, thereby promoting the transition of cells from an epithelial to a mesenchymal state. This transition is crucial for processes such as embryonic development, wound healing, and maintaining tissue homeostasis (Nieto2002The; Jung2019Apical–basal).

In healthy cells, SNAI1 is involved in maintaining epithelial characteristics by regulating its own stability through phosphorylation. The PAR3-aPKC complex phosphorylates SNAI1, leading to its ubiquitination and degradation, which prevents EMT and maintains epithelial integrity. This regulatory mechanism is crucial for preventing pathological transitions such as tumor metastasis (Jung2019Apical–basal).

SNAI1 is also implicated in endothelial-mesenchymal transition (EndMT), influencing angiogenesis by affecting cell motility and invasion. It modulates the expression of genes involved in cytoskeleton arrangement and extracellular matrix remodeling, which are vital for angiogenesis and vascular development (Sun2018SNAI1).

## Clinical Significance
Alterations in the expression of the SNAI1 gene have significant clinical implications in various cancers. In colorectal cancer (CRC), SNAI1 is involved in epithelial-mesenchymal transition (EMT), contributing to cancer invasiveness and chemoresistance. Phosphorylation-defective variants of SNAI1, such as SNAI1-6SA and SNAI1-8SA, lead to downregulation of E-cadherin and upregulation of vimentin, enhancing the invasive ability of CRC cells and increasing resistance to the chemotherapeutic agent 5-fluorouracil (Hoshino2009Epithelial–mesenchymal).

In prostate cancer, SNAI1 overexpression is linked to increased aggressiveness, particularly in cells with low E-cadherin expression. It promotes EMT, enhances cancer stem cell activity, and is associated with poor clinical outcomes, such as higher Gleason scores and advanced clinical stages (Deep2014SNAI1).

In acute myeloid leukemia (AML), SNAI1 is overexpressed and interacts with the histone demethylase LSD1, altering myeloid differentiation and promoting leukemia development. This interaction is crucial for the pathogenesis of AML, suggesting that targeting the SNAI1-LSD1 complex could be a potential therapeutic strategy (Carmichael2020The).

## Interactions
SNAI1, also known as Snail1, is a transcription factor that plays a significant role in epithelial-mesenchymal transition (EMT) by interacting with various proteins to regulate gene expression. One of its key interactions is with lysine-specific demethylase 1 (LSD1), facilitated by the SNAG domain of SNAI1, which mimics the structure of the histone H3 tail. This interaction is crucial for the demethylation of H3K4me2 at the E-cadherin promoter, leading to transcriptional repression (Lin2010The). SNAI1 also recruits the CoREST complex, enhancing the stability and function of the SNAI1-LSD1 complex (Lin2010The).

SNAI1 interacts with components of the PRC2 complex, such as EZH2 and Suz12, to induce H3K27 trimethylation, further repressing E-cadherin expression (Lin2010The). It also forms a ternary complex with PRMT5 and Ajuba, increasing arginine methylation of H4R3 at the E-cadherin promoter (Lin2010The). Additionally, SNAI1 associates with the Sin3A-HDAC1/2 complex to deacetylate histones H3 and H4, contributing to the suppression of E-cadherin (Gao2019SNAI1; Lin2010The).

In the context of acute myeloid leukemia (AML), SNAI1 competes with other co-factors for LSD1 binding, altering myeloid differentiation and contributing to AML progression (Carmichael2020The).


## References


[1. (Gao2019SNAI1) Ning Gao, Jingming Li, Yazhou Qin, Yingna Wang, Qianyang Kang, and Cheng Pei. Snai1 interacts with hdac1 to control tgf‑β2‑induced epithelial‑mesenchymal transition in human lens epithelial cells. International Journal of Molecular Medicine, November 2019. URL: http://dx.doi.org/10.3892/ijmm.2019.4405, doi:10.3892/ijmm.2019.4405. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijmm.2019.4405)

[2. (Nieto2002The) M. Angela Nieto. The snail superfamily of zinc-finger transcription factors. Nature Reviews Molecular Cell Biology, 3(3):155–166, March 2002. URL: http://dx.doi.org/10.1038/nrm757, doi:10.1038/nrm757. This article has 1333 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrm757)

[3. (Lin2010The) Yiwei Lin, Yadi Wu, Junlin Li, Chenfang Dong, Xiaofeng Ye, Young-In Chi, B Mark Evers, and Binhua P Zhou. The snag domain of snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. The EMBO Journal, 29(11):1803–1816, April 2010. URL: http://dx.doi.org/10.1038/emboj.2010.63, doi:10.1038/emboj.2010.63. This article has 278 citations.](https://doi.org/10.1038/emboj.2010.63)

[4. (Hoshino2009Epithelial–mesenchymal) Hiromitsu Hoshino, Norikatsu Miyoshi, Ken-ichi Nagai, Yoshito Tomimaru, Hiroaki Nagano, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori, and Hideshi Ishii. Epithelial–mesenchymal transition with expression of snai1-induced chemoresistance in colorectal cancer. Biochemical and Biophysical Research Communications, 390(3):1061–1065, December 2009. URL: http://dx.doi.org/10.1016/j.bbrc.2009.10.117, doi:10.1016/j.bbrc.2009.10.117. This article has 59 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2009.10.117)

[5. (Jung2019Apical–basal) Hae-Yun Jung, Laurent Fattet, Jeff H. Tsai, Taketoshi Kajimoto, Qiang Chang, Alexandra C. Newton, and Jing Yang. Apical–basal polarity inhibits epithelial–mesenchymal transition and tumour metastasis by par-complex-mediated snai1 degradation. Nature Cell Biology, 21(3):359–371, February 2019. URL: http://dx.doi.org/10.1038/s41556-019-0291-8, doi:10.1038/s41556-019-0291-8. This article has 97 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41556-019-0291-8)

[6. (Razmara2021Functions) Ehsan Razmara, Amirreza Bitaraf, Behnaz Karimi, and Sadegh Babashah. Functions of the snai family in chondrocyte‐to‐osteocyte development. Annals of the New York Academy of Sciences, 1503(1):5–22, August 2021. URL: http://dx.doi.org/10.1111/nyas.14668, doi:10.1111/nyas.14668. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/nyas.14668)

[7. (Sun2018SNAI1) Jia-Xing Sun, Tian-Fang Chang, Man-Hong Li, Li-Juan Sun, Xian-Chun Yan, Zi-Yan Yang, Yuan Liu, Wen-Qin Xu, Yang Lv, Jing-Bo Su, Liang Liang, Hua Han, Guo-Rui Dou, and Yu-Sheng Wang. Snai1, an endothelial–mesenchymal transition transcription factor, promotes the early phase of ocular neovascularization. Angiogenesis, 21(3):635–652, April 2018. URL: http://dx.doi.org/10.1007/s10456-018-9614-9, doi:10.1007/s10456-018-9614-9. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10456-018-9614-9)

[8. (Deep2014SNAI1) Gagan Deep, Anil K Jain, Anand Ramteke, Harold Ting, Kavitha C Vijendra, Subhash C Gangar, Chapla Agarwal, and Rajesh Agarwal. Snai1 is critical for the aggressiveness of prostate cancer cells with low e-cadherin. Molecular Cancer, 13(1):37, 2014. URL: http://dx.doi.org/10.1186/1476-4598-13-37, doi:10.1186/1476-4598-13-37. This article has 65 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/1476-4598-13-37)

[9. (Carmichael2020The) Catherine L. Carmichael, Jueqiong Wang, Thao Nguyen, Oluseyi Kolawole, Aissa Benyoucef, Charlotte De Mazière, Anna R. Milne, Sona Samuel, Kevin Gillinder, Soroor Hediyeh-zadeh, Anh N. Q. Vo, Yizhou Huang, Kathy Knezevic, William R. L. McInnes, Benjamin J. Shields, Helen Mitchell, Matthew E. Ritchie, Tim Lammens, Beatrice Lintermans, Pieter Van Vlierberghe, Nicholas C. Wong, Katharina Haigh, Julie A. I. Thoms, Emma Toulmin, David J. Curtis, Ethan P. Oxley, Ross A. Dickins, Dominik Beck, Andrew Perkins, Matthew P. McCormack, Melissa J. Davis, Geert Berx, Johannes Zuber, John E. Pimanda, Benjamin T. Kile, Steven Goossens, and Jody J. Haigh. The emt modulator snai1 contributes to aml pathogenesis via its interaction with lsd1. Blood, 136(8):957–973, August 2020. URL: http://dx.doi.org/10.1182/blood.2019002548, doi:10.1182/blood.2019002548. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood.2019002548)

[10. (Dong2021Epigenetic) Bo Dong and Yadi Wu. Epigenetic regulation and post-translational modifications of snai1 in cancer metastasis. International Journal of Molecular Sciences, 22(20):11062, October 2021. URL: http://dx.doi.org/10.3390/ijms222011062, doi:10.3390/ijms222011062. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222011062)